We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Circio Holding ASA (CRNA) NOK0.6

Sell:2.04 NOK Buy:2.29 NOK Change: 0.04 NOK (1.81%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:2.04 NOK
Buy:2.29 NOK
Change: 0.04 NOK (1.81%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:2.04 NOK
Buy:2.29 NOK
Change: 0.04 NOK (1.81%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.

Contact details

Address:
Vollsveien 19
LYSAKER
1366
Norway
Telephone:
+47 (2) 1398810
Website:
https://www.circio.com/en/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRNA
ISIN:
NO0013033795
Market cap:
69.36 million NOK
Shares in issue:
31.39 million
Sector:
Biotechnology
Exchange:
Oslo Stock Exchange
Country:
Norway
Currency:
Norwegian Krone
Indices:
Oslo All Share Index

Key personnel

  • Damian Marron
    Chairman of the Board
  • Erik Digman Wiklund
    Chief Executive Officer
  • Lubor Gaal
    Chief Financial Officer
  • Jon Eriksen
    Chief Operating Officer
  • Antti Vuolanto
    Executive Vice President
  • Victor Levitsky
    Chief Scientific Officer
  • Anne Aksnes
    Vice President, Clinical Development
  • Tina Madsen
    Vice President, Quality Assurance
  • Peter Skorpil
    Vice President, Business Development
  • Nikolaj Knudtzon
    Head of HR

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.